Literature DB >> 10219676

High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.

A Kurita1, N Kaneda.   

Abstract

We established a high-performance liquid chromatography (HPLC) method for the simultaneous determination of the camptothecin (CPT) derivative, irinotecan hydrochloride (CPT-11) and its metabolites, 7-ethyl-10-hydroxycamptothecin (SN-38) and SN-38 glucuronide (SN-38G) in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. Plasma samples were pretreated with 0.146 M H3PO4 to inactivate carboxylesterase and beta-glucuronidase in rat plasma, and added with the internal standard solution (0.146 M H3PO4 containing 1 microgram/ml CPT) and then analyzed. The method was validated for CPT-11 (5 to 25,000 ng/ml), SN-38 (5 to 2500 ng/ml) and SN-38G (2.5 to 500 ng/ml). This method enabled the determination of many samples within a relatively short time with easy sample preparation. It also had four advantages compared with conventional determination methods, i.e. automation of a complicated sample preparation, time-saving by the simultaneous determination of three compounds, the direct determination of SN-38G, and the small amount of plasma required for the determination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219676     DOI: 10.1016/s0378-4347(98)00554-4

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  9 in total

1.  Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

Authors:  Xiaohong Chen; Cody J Peer; Raul Alfaro; Tian Tian; Shawn D Spencer; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2012-01-16       Impact factor: 3.935

2.  Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.

Authors:  Akira Takakura; Akinobu Kurita; Takashi Asahara; Masanori Yokoba; Michiko Yamamoto; Shinichiro Ryuge; Satoshi Igawa; Yukitoshi Yasuzawa; Jiichiro Sasaki; Hirosuke Kobayashi; Noriyuki Masuda
Journal:  Oncol Lett       Date:  2011-12-09       Impact factor: 2.967

3.  Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model.

Authors:  Piyun Chao; Manjeet Deshmukh; Hilliard L Kutscher; Dayuan Gao; Sujata Sundara Rajan; Peidi Hu; Debra L Laskin; Stanley Stein; Patrick J Sinko
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

4.  Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.

Authors:  Koichi Hirose; Chihiro Kozu; Koshiro Yamashita; Eiji Maruo; Mizuho Kitamura; Junichi Hasegawa; Kei Omoda; Teruo Murakami; Yorinobu Maeda
Journal:  Oncol Lett       Date:  2011-12-22       Impact factor: 2.967

5.  Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.

Authors:  Huali Wu; Jeffrey R Infante; Vicki L Keedy; Suzanne F Jones; Emily Chan; Johanna C Bendell; Wooin Lee; Beth A Zamboni; Satoshi Ikeda; Hiroshi Kodaira; Mace L Rothenberg; Howard A Burris; William C Zamboni
Journal:  Eur J Clin Pharmacol       Date:  2013-08-30       Impact factor: 2.953

6.  A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.

Authors:  Y Takeda; E Tsuduki; S Izumi; M Hojo; M Kamimura; G Naka; K Kobayashi; K Kudo
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

7.  Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

Authors:  Huali Wu; Jeffrey R Infante; Vicki L Keedy; Suzanne F Jones; Emily Chan; Johanna C Bendell; Wooin Lee; Whitney P Kirschbrown; Beth A Zamboni; Satoshi Ikeda; Hiroshi Kodaira; Mace L Rothenberg; Howard A Burris; William C Zamboni
Journal:  Int J Nanomedicine       Date:  2015-02-10

8.  Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation.

Authors:  Wenqian Yang; Zimeng Yang; Jieru Liu; Dan Liu; Yongjun Wang
Journal:  Asian J Pharm Sci       Date:  2018-09-11       Impact factor: 6.598

9.  A pharmacokinetic-pharmacodynamic model based on multi-organ-on-a-chip for drug-drug interaction studies.

Authors:  Kenta Shinha; Wataru Nihei; Tatsuto Ono; Ryota Nakazato; Hiroshi Kimura
Journal:  Biomicrofluidics       Date:  2020-07-23       Impact factor: 2.800

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.